Expertise in
23
conditions

Dr. Zachary S. Zumsteg

Radiation Oncology
Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, 
West Hollywood, CA 
Offers Telehealth
Expertise in
23
conditions
Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, 
West Hollywood, CA 

Overview

Zachary Zumsteg is a Radiation Oncologist practicing medicine in West Hollywood, California.

Dr. Zumsteg is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Laryngeal Cancer, Throat Cancer, Prostatectomy, and Thyroidectomy.

He is actively involved in clinical research, co-authoring 133 peer reviewed articles and participating in 9 clinical trials.

Specialties

Radiation Oncology

Hospital Affiliations

Cedars-Sinai Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Radiation, Procedure
Study Phase: Early Phase 1
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 8 Less Clinical Trials

133 Total Publications

Single-cell transcriptomic analysis reveals tumor-immune determinants of lymph node colonization and progression in thyroid cancer.
Single-cell transcriptomic analysis reveals tumor-immune determinants of lymph node colonization and progression in thyroid cancer.
Journal: Science advances
Published: July 03, 2026
Similar Doctors
Expertise in
21
conditions
Dr. Mitchell R. Kamrava
Radiation Oncology
Expertise in
21
conditions
Dr. Mitchell R. Kamrava
Radiation Oncology
Referral may be required

Cedars-Sinai Radiation Oncology-Los Angeles

8720 Beverly Blvd, 
West Hollywood, CA 
 (0.1 miles away)
310-423-4208
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mitchell Kamrava is a Radiation Oncologist practicing medicine in West Hollywood, California. Dr. Kamrava is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Vaginal Cancer, Prostate Cancer, Prostatectomy, and Vitrectomy.

Expertise in
10
conditions
Dr. Leslie K. Ballas
Radiation Oncology
Expertise in
10
conditions
Dr. Leslie K. Ballas
Radiation Oncology
Referral may be required

Cedars-Sinai Radiation Oncology-Los Angeles

8720 Beverly Blvd, 
West Hollywood, CA 
 (0.1 miles away)
310-423-4208
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leslie Ballas is a Radiation Oncologist practicing medicine in West Hollywood, California. Dr. Ballas is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Muscle Invasive Bladder Cancer, Prostate Cancer, Familial Prostate Cancer, Bladder Reconstruction, and Prostatectomy.

Expertise in
35
conditions
Dr. Tania B. Kaprealian
Radiation Oncology
Expertise in
35
conditions
Dr. Tania B. Kaprealian
Radiation Oncology
Referral may be required

Office

200 Medical Plz, 
Los Angeles, CA 
 (3.8 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tania Kaprealian is a Radiation Oncologist practicing medicine in Los Angeles, California. Dr. Kaprealian is highly rated in 35 conditions, according to our data. Her clinical expertise encompasses Meningioma, Radiation Induced Meningioma, Metastatic Brain Tumor, Schwannoma, and Thalamotomy.

Frequently Asked Questions about Dr. Zachary S. Zumsteg

How do I make an appointment with Dr. Zachary S. Zumsteg?

You can book an appointment with Dr. Zachary S. Zumsteg by calling their office at 310-423-4208. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Zachary S. Zumsteg a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Zachary S. Zumsteg is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Zachary S. Zumsteg specialize in?

While Dr. Zachary S. Zumsteg is a Radiation Oncology, they have specific expertise in Prostate Cancer, Laryngeal Cancer, and Throat Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Zachary S. Zumsteg participate in research or clinical trials?

Yes. Dr. Zachary S. Zumsteg has published 133 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Zachary S. Zumsteg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Zachary S. Zumsteg accept my insurance?

Dr. Zachary S. Zumsteg accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 310-423-4208 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zumsteg's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile